A Phase 2 Study of the Efficacy and Safety of ACP-196 in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 17 Aug 2017
At a glance
- Drugs Acalabrutinib (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- Sponsors Acerta Pharma
- 10 Aug 2017 Status changed from recruiting to active, no longer recruiting.
- 20 Oct 2016 Planned number of patients changed from 80 to 60.
- 29 Mar 2016 New trial record